key: cord-1053923-m8195kqt
authors: Mader, Christoph; Bernatz, Simon; Michalik, Sabine; Koch, Vitali; Martin, Simon S.; Mahmoudi, Scherwin; Basten, Lajos; Grünewald, Leon D.; Bucher, Andreas; Albrecht, Moritz H.; Vogl, Thomas J.; Booz, Christian
title: Quantification of COVID-19 opacities on chest CT – evaluation of a fully automatic AI-approach to non-invasively differentiate critical versus non-critical patients
date: 2021-03-06
journal: Acad Radiol
DOI: 10.1016/j.acra.2021.03.001
sha: 1b9d7d1ff737e6cd3ecf836b7a12d0316775a891
doc_id: 1053923
cord_uid: m8195kqt

OBJECTIVES: : To evaluate the potential of a fully automatic artificial intelligence (AI)-driven computed tomography (CT) software prototype to quantify severity of COVID-19 infection on chest CT in relationship with clinical and laboratory data. METHODS: : We retrospectively analyzed 50 patients with laboratory confirmed COVID-19 infection who had received chest CT between March and July 2020. Pulmonary opacifications were automatically evaluated by an AI-driven software and correlated with clinical and laboratory parameters using Spearman-Rho and linear regression analysis. We divided the patients into subcohorts with or without necessity of intensive care unit (ICU) treatment. Subcohort differences were evaluated employing Wilcoxon-Mann-Whitney-Test. RESULTS: : We included 50 CT examinations (mean age, 57.24 years), of whom 24 (48%) had an ICU stay. Extent of COVID-19 like opacities on chest CT showed correlations (all P<0.001 if not otherwise stated) with occurrence of ICU stay (R=0.74), length of ICU stay (R=0.81), lethal outcome (R=0.56) and length of hospital stay (R=0.33, P<0.05). The opacities extent was correlated with laboratory parameters: neutrophil count (NEU) (R=0.60), lactate dehydrogenase (LDH) (R=0.60), troponin (TNTHS) (R=0.55) and c-reactive protein (CRP) (R=0.51). Differences (P<0.001) between ICU group and non-ICU group concerned longer length of hospital stay (24.04 vs. 10.92 days), higher Opacityscore (12.50 vs. 4.96) and severity of laboratory data changes such as CRP (11.64 vs. 5.07 mg/dl, P<0.01). CONCLUSIONS: : Automatically AI-driven quantification of opacities on chest CT correlates with laboratory and clinical data in patients with confirmed COVID-19 infection and may serve as non-invasive predictive marker for clinical course of COVID-19.

admission (approximately 30%) with consecutive high mortality rates (up to 15%) (3) .

Although real-time reverse transcription polymerase-chain-reaction (RT-PCR) is considered to be the current gold standard for diagnosing, the method is slow and has a high false negative rate (4) . Among the 1014 COVID-Patients in Wuhan up to February 6, 2020 only 59% had a positive RT-PCR result, whereas 88% showed positive findings on chest computed tomography (CT) scans (4) . Chest CT therefore may not only be able to detect more cases of viral pneumonia in terms of but also to quantify the severity of pulmonary COVID-19 manifestation (5) . Frequently reported findings in chest CT were bilateral and peripheral ground-glass opacities (GGO), crazy-paving pattern, and consolidations (6) .

Some studies have analyzed the relationship between the severity of abnormalities on chest CT scans in COVID-19 positive patients with clinical and laboratory data. Xiong et al. showed that laboratory data like CRP, erythrocyte sedimentation rate and LDH correlated with the severity of abnormalities manually quantified on chest CT scans (7) . Lanza et al. found that semi-automatic quantification of compromised lung volume in COVID-19 patients on chest CT scans correlated with the need for oxygenation support and intubation and might therefore serve as a triaging and prediction tool in COVID-19 positive patients (8) . However, manual and semiautomatic quantification and feature extraction of pulmonary opacifications is timeconsuming and prone to inter-observer variance complicating implementation in clinical routine (9) . In this context, the application of fully automatic deep learning models may enable radiologists to make a more accurate diagnosis and quantification of corresponding lung changes in terms of severity assessment (9) (10) (11) (12) .

In addition, software-based analysis of chest CT scans may improve time-efficiency in clinical routine, which gets more and more important in context of increasing examination numbers. Anyhow, there has been no diagnostic model based on medical imaging without high risk of bias so far. Studies often lack information regarding how regions of interest are annotated which results in no transparency and reproducibility of the models (13) .

Recently, a new software prototype for fully automatic quantification of COVID-19 like lung opacities on chest CT scans has been developed. This prototype offers several advantages in that it is fast, fully-automatic, provides two combined severity measures of the disease and can be used on CT scans with a slice thickness up to 5 mm (14) .

In this initial study, we aimed at evaluating the potential of this prototype for fully automatic quantification of COVID-19 like opacities on chest CT scans of 50 laboratory confirmed COVID-19 patients in relation with clinical and laboratory data.

The study was approved by the ethical review board of our institution. Written informed consent was obtained for experimentation with human subjects. All investigations were conducted in accordance with the 1964 Declaration of Helsinki and its amendments.

This retrospective study was approved by the local ethics committee. Written informed consent was waived. Two radiologists (*BLINDED* and *BLINDED*) scanned our Picture Archiving and Communication System (PACS) and Radiology Information System (RIS) for a total of 151 patients, who had received chest CT scans at our institution in case of suspicion for a COVID-19 infection in the period from 1 st of March 2020 to 31th of July 2020. COVID-19 infection was RT-PCRapproved in 50 cases with a positive real-time fluorescence polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 nucleic acid with nasopharyngeal or oropharyngeal swab specimens. Negative SARS-CoV-2 RT-PCR as well as patients who did not fulfill inclusion criteria (children <18 years, slice thickness > 5 mm, artifacts) were excluded (Fig. 1) . Demographics, typical COVID-19 symptoms, and laboratory data were retrospectively collected from the electronic medical records platform. CRP, LDH, TNTHS, NEU, procalcitonin (PCT), d-dimers (DDI), white blood cell count (LEU), lymphocyte count (LYM), thrombocyte count (THR), interleukin-6 (IL6), bilirubin (BIL), lactate (LAC), alanine aminotransferase (GPT), quick value (TPZ), creatinine (KREA) and urea (HST) were collected at the time point of CT performance (±48 h) and were analyzed to examine a possible relation with automated quantification of abnormalities associated with COVID-19. Time interval between onset of symptoms and imaging at our institution, length of hospital stay, length of ICU stay and outcome of the patients were collected. For subcohort analysis, patients were divided into a critical (n=24) and non-critical group (n=26) based on necessity of an ICU stay.

Unenhanced chest CT examinations were carried out on two 192-detector row, 3 rd generation CT scanners (SOMATOM Force, Siemens Healthineers, Forchheim, Germany [critical patients, n=10; non-critical, n=12] and SOMATOM Definition AS, Siemens Healthineers [critical, n=14; non-critical, n=14]). A tube voltage of 120 kV and automatic tube current modulation (100-400 mA) were used. Images were reconstructed with a slice thickness between 1.00 mm to 5.00 mm (1.00 mm = 42/50 (0.84), 5.00 mm = 8/50 (0.16)). The average time interval between initial chest CT performance and onset of symptoms was 13.08 days (range, 2-45 days).

The software used to quantify COVID-19 like abnormalities of the lung calculates percentage of opacity (PO) and lung severity score (LSS) by segmenting threedimensional abnormalities like ground glass opacities and consolidations, that were related to COVID-19. Thereby PO and LSS define the expanse of lung involvement and allocation of involvement across lobes. High opacity abnormalities like consolidations and subsolid regions were measured by percentage of high opacity (PHO) and lung high opacity score (LHOS), which define the extent of high opacity abnormalities and the distribution across the lung lobes. By default, a Hounsfield Unit (HU) threshold of -200 HU was applied for identification of high opacities. A lobe was classified as "affected" if the algorithm detected high opacity abnormalities in the defined lung part.

The overall extent of opacities is displayed by a reproducible, fully automatically calculated so called Opacityscore ranging from 0-20, which is a sum up of the five lung lobes. An Opacityscore of 0 means that none of the lobes is affected whereas 20 represents extensive involvement of all five lobes. Lobe-wise, the score is calculated on the percentage of opacity per lobe, using a Likert scale from 0 to 4.

Percentage of opacity -which represents the percentage of predicted volume of abnormalities compared to the total lung volume within a given region -is classified as follows: score = 0, 1, 2, 3 ,4 extent of opacity within a given region ≤1%, ≤25%, ≤50, ≤75%, >75%, respectively (Fig. 3) .

The software is based on AI algorithms to automatically identify and quantify lung hyperdensities for research purposes (Fig. 2) . Multi-scale deep reinforcement learning (15) was used for anatomical landmark detection and a Deep Image to Image Network (DI2IN) (16) for segmentation, based on a dataset of 8792 CT volumes. To ensure a stable lobe-wise segmentation and identification of abnormal patterns, the DI2IN was trained on 8087 patients with various diseases and afterwards fine-tuned on another dataset of 1136 patients with similar abnormalities as COVID-19 like GGO and consolidation (e.g. viral pneumonia, interstitial lung diseases). The algorithm was finally evaluated on 100 control volumes without pathological chest-CT findings and 100 patients with confirmed COVID-19. The Pearson correlation coefficient between method prediction and ground truth for COVID-19 positive scans was calculated as 0.92 for PO (P < .001), 0.97 for PHO (P < .001), 0.91 for LSS (P < .001), 0.9 for LHOS (P < .001) (14) . For further information we recommend the recently published study by Chaganti et al (14) .

Automatic segmentation was visually approved by two radiologists (*BLINDED* and *BLINDED*) in each examination. In no cases pleural effusions or other findings affected the software-based severity measurement. No manual adjustment was performed in order to reduce manual manipulation and to examine a fully automated quantification approach.

Statistical analysis was conducted using RStudio (Version 1.2.5001, RStudio, Inc.).

Demographics and clinical characteristics were analyzed applying descriptive statistics. Correlation coefficients were calculated using Spearman-rho. Differences between groups were calculated using Wilcoxon-Mann-Whitney-Test. Levels of significance are depicted as followed: * P< 0.05; ** P<0.01; ***P<0.001.

The study included a total of 50 patients (44 male). Mean age was 57.24 years (range, 35-85 years). Common comorbidities of the patients included hypertension (17/50, 34%), cardiovascular disease (13/50, 26%), diabetes (10/50, 20%), chronic kidney disease (7/50, 14%). chronic lung disease (6/50, 12%) and malignancy (4/50, 

We could reveal highest correlation coefficients (all P<0.001 if not otherwise stated) between the Opacityscore and clinical data such as occurrence of an ICU stay 

In this study we evaluated the potential of a state-of-the-art AI-driven software Certain studies have shown that quantitative analysis of COVID-19 like lung findings on chest CT is correlated with clinical and laboratory data and partially might be superior to previous clinical biomarkers in predicting COVID-19 progression to severe illness (8, 18, 19 ). Nevertheless, manual or semi-automatic quantification of lung lesions on chest CT scans is still prone to inter-observer variance and remains time-consuming (9) . In order to reduce bias inherent in semiautomatic analyses we decided to apply a fully automatic software solution to quantify CT scans providing the advantage of a short analysis time and absence of inter-observer variance (14) .

The prototype applied in our study represents a major step towards transparency and standardization in COVID-19 diagnostics. The software is based on a comprehensible algorithm; the quantification is fully automatic, fast and offers standardized numeric scores in order to quantify the extent of the disease (14) .

Furthermore, the color-coded illustration of lung lobes enables an easy comprehension and review of the software's analyses. Spatial distribution of opacities can be quickly overviewed by using VRT reconstructions and the high opacity threshold is configurable. Considering that all patients with lethal outcome in this study had a significantly higher Opacityscore than survivors and the fact that risk models are often based on multiple data which are not directly accessible during an epidemic (20), the use of the software parameters as risk predictors may serve as clinical decision support tool though validity still needs to be elucidated. In addition, the prototype analyses CT scans with a slice thickness of up to 5 mm. Since AI algorithms usually require HR-CT which is frequently associated with consecutive higher radiation and higher costs, the software could be used more widely (e.g. in developing countries) and may contribute to a lower radiation exposure in certain cases (21).

The results of this study are in accordance with previously published results demonstrating that COVID-19 infection contributes to changes in clinical and laboratory parameters -particularly increased CRP, IL-6, LDH and caused lymphopenia -which were significantly associated with disease severity (22-24). DDI and TNTHS showed significant correlations with Opacityscore in COVID-19 patients, who are known to have an increased risk of acute pulmonary embolism (25) and might have long-term cardiovascular consequence (26). Our findings may indicate that the level of lung manifestation could also be associated with a higher probability of concomitant diseases. Furthermore, this study supports previous findings in terms of association between quantification features and clinical parameters (8, 27) . ICU and non-ICU patients significantly differed in Opacityscore. This is in line with a previously published study describing significant differences in lung opacification percentage among patients with different clinical severity, such as an increased opacity percentage from baseline CT to first follow-up (12) . Also, Colombi et al observed that a well-ventilated lung parenchyma of less than 73% on CT on hospital admission was significantly associated with subsequent admission to ICU or death (18) . In face of the disadvantage of semi-automatic quantification methods, softwarederived parameters might have the potential to predict severity of illness and clinical course and to enable early stratification of critical patients in a fully automatic manner. In addition, the automatic quantification enables an objective evaluation of the COVID-19 like changes independent from the experience of radiologists, which can play a major role in the assessment of the disease, especially for unexperienced observers (28) (29) (30) . This study had several limitations beyond the retrospective study design that need to be adressed. First, correlation does not mean causation. Although COVID-19 might have influenced ICU admission for a certain part, comorbidities could not be deducted. Second, the patient population size was relatively small; studies with larger patient populations are necessary to confirm our results and to further evaluate the potential of the applied software prototype. Third, not all laboratory data were collected on the date of CT performance (± 48 h), which may have influenced the results. In addition, the course of laboratory data changes was not included into the correlation analysis in this study. Fourth, CT examinations were carried out at various disease stage due to individual reasons. Fifth, the applied AI-driven software is vendor-specific and currently only applicable on a dedicated research postprocessing platform. Sixth, the difference between radiologist and software performance in quantification of COVID-19 like opacities has not been adressed by us in this study.

In this initial study, we demonstrated that fully automatic quantification of COVID-19 like opacities using a software prototype is feasible in clinical routine. The Opacityscore correlated with clinical and laboratory data in confirmed COVID-19 patients. Furthermore, ICU and non-ICU patients significantly differed regarding the Opacityscore. Therefore, the automatically computed software parameters offer several advantages compared to semi-automatic quantification methods and might serve as a predictive marker for clinical course of COVID-19 and enable early noninvasive stratification of patients with prognostic and therapeutic relevance.

Prospective multicenter studies are required to evaluate software robustness and to further validate translation into clinical practice.

Liu F, Zhang Q, Huang C, et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. 

This research did not receive any specific grant from funding agencies in the public, commercial, or non-for-profit sectors.

Flow chart of patient inclusion. 

COVID-19): A Perspective from China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Correlation of Chest CT and RT-PCR Testing for

COVID-19) in China: A Report of 1014 Cases

CO-RADS -A categorical CT assessment scheme for patients with suspected COVID-19: definition and evaluation

CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)

Clinical and High-Resolution CT Features of the COVID-19 Infection: Comparison of the Initial and Follow-up Changes

Quantitative chest CT analysis in COVID-19 to predict the need for oxygenation support and intubation

Lung Infection Quantification of COVID-19 in CT

AI Augmentation of Radiologist Performance in Distinguishing COVID-19 from Pneumonia of

Deep-Learning Approach

Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal

Automated Quantification of CT Patterns Associated with COVID-19 from Chest CT

Multi-Scale Deep Reinforcement Learning for Real-Time 3D-Landmark Detection in CT Scans

Automatic Liver Segmentation Using an

Adversarial Image-to-Image Network

Deep learning-based multi-view fusion model for screening 2019 novel coronavirus pneumonia: A multicentre study

Well-aerated Lung on Admitting Chest CT to Predict Adverse Outcome in COVID-19 Pneumonia

Quantitative analysis of chest CT imaging findings with the risk of ARDS in COVID-19 patients: a preliminary study

COVID-19 severity scoring systems in radiological imaging -a review

Truncated inception net: COVID-19 outbreak screening using chest X-rays

CT image segmentation for inflamed and fibrotic lungs using a multi-resolution convolutional neural network

Artificial intelligence for the detection of COVID-19 pneumonia on chest CT using multinational datasets

Value of minimum intensity projections for chest CT in COVID-19 patients

Integrative analysis for COVID-19 patient outcome prediction

Data are p values, calculated using Wilcoxon-Mann-Whitney-Test